Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (121-130 of 260) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
Gynecologic Oncology|June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractMichael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2018
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumorsMary E R O'Brien, Debashis Sarker, Jaishree Bhosle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid TumorsTimothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?Marta Capelan, Desamparados Roda, Elena Geuna, et al.
BMC Research Notes|November 20, 2015
Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practiceFatma Abdelraouf, Adam Sharp, Manisha Maurya, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Investigational New Drugs|September 1, 2021
A phase i study of ixazomib and erlotinib in patients with advanced solid tumorsShumei Kato, Jacob J Adashek, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.
Cancer Treatment Reviews|June 22, 2025
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging StrategiesFederica Giugliano, Carmine De Angelis, Barbara Pistilli, et al.
Pageof 26

Showing results (121-130 of 260) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical TrialsSaeed Rafii, Desamparados Roda, Elena Geuna, et al.
Gynecologic Oncology|June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractMichael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
Cancer Chemotherapy and Pharmacology|August 9, 2018
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumorsMary E R O'Brien, Debashis Sarker, Jaishree Bhosle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid TumorsTimothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?Marta Capelan, Desamparados Roda, Elena Geuna, et al.
BMC Research Notes|November 20, 2015
Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practiceFatma Abdelraouf, Adam Sharp, Manisha Maurya, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Investigational New Drugs|September 1, 2021
A phase i study of ixazomib and erlotinib in patients with advanced solid tumorsShumei Kato, Jacob J Adashek, Vivek Subbiah, et al.
Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.
Cancer Treatment Reviews|June 22, 2025
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging StrategiesFederica Giugliano, Carmine De Angelis, Barbara Pistilli, et al.
Pageof 26